Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

每经AI快讯，1月22日，恩华药业(002262.SZ)公告称，公司近日获得国家药品监督管理局核准签发的化 学药品右酮洛芬氨丁三醇注射液的《药品注册证书》。该药品是一种非甾体抗炎镇痛药，作为阿片类镇 痛药的辅助，用于成人不适合口服给药的急性中度至重度术后疼痛。右酮洛芬氨丁三醇注射液为公司首 个围手术期注射用非甾体抗炎药（NSAIDs），其上市销售将对公司今后业绩的提升产生积极的影响。 ...

恩华药业1月22日公告，公司近日获得国家药品监督管理局核准签发的化学药品右酮洛芬氨丁三醇注射 液的《药品注册证书》。右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是COX-1 和COX-2 活性 的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度术后疼痛。 ...

格隆汇1月22日丨恩华药业(002262.SZ)公布，公司于近日获得国家药品监督管理局核准签发的化学药品 右酮洛芬氨丁三醇注射液的《药品注册证书》，右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是 COX-1和COX-2活性的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度 术后疼痛。本品镇痛效果和安全性良好，可明显减少术后阿片类药物的用量。根据国家药品监督管理局 药品数据显示，目前该品种国内只有南京正科医药股份有限公司获得批准。 ...

恩华药业公告，公司于近日获得国家药品监督管理局核准签发的化学药品右酮洛芬氨丁三醇注射液的 《药品注册证书》。右酮洛芬氨丁三醇注射液为公司首个围手术期注射用非甾体抗炎药（NSAIDs）， 本次获得右酮洛芬氨丁三醇注射液的《药品注册证书》，丰富了公司在镇痛用药领域的产品管线，有利 于提升公司的市场竞争力，其上市销售将对公司今后业绩的提升产生积极的影响。 ...

恩华药业公告称，近日获国家药监局核准签发的化学药品右酮洛芬氨丁三醇注射液《药品注册证书》， 规格为2ml:50mg，剂型为注射剂，有效期24个月，批准文号有效期至2031年1月13日。该药品是一种非 甾体抗炎镇痛药，用于成人不适合口服给药的急性中度至重度术后疼痛。这是公司首个围手术期注射用 非甾体抗炎药，丰富了产品管线，将提升市场竞争力和业绩。不过，生产销售可能受不确定因素影响。 ...

智通财经APP讯，恩华药业(002262.SZ)公告，公司近日获得国家药品监督管理局核准签发的化学药品右 酮洛芬氨丁三醇注射液的《药品注册证书》。右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是 COX-1和COX-2活性的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度 术后疼痛。 ...